Viewing nowCombinationActosril 30/4 mg tablet
Pioglitazone Hydrochloride 33.06mg · Glimepiride 4mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 201309845 · Approved 2013.10.21 · Insurance code 693903500
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve blood glucose control in patients with type 2 diabetes who are appropriate candidates for combined therapy with glimepiride and pioglitazone.
The dose of this drug should be individualized based on the patient's efficacy and tolerability. Take this drug once daily with breakfast. 1. Patients whose blood glucose is not adequately controlled with glimepiride monotherapy: The dose should be based on the patient's current glimepiride dose. Considering the initial concomitant dose of pioglitazone (15mg per day), pioglitazone 15mg may be administered with glimepiride. After assessing the adequacy of the treatment response, this drug may be administered once daily as a pioglitazone/glimepiride 30mg/2mg or 30mg/4mg tablet. 2. Patients switching to this drug from concomitant therapy with pioglitazone and glimepiride: Based on the patient's existing doses of pioglitazone and glimepiride, this drug may be administered at the same dose as a 30mg/2mg or 30mg/4mg tablet. Maximum recommended dose This drug is an oral formulation containing 30mg pioglitazone + 2mg glimepiride or 30mg pioglitazone + 4mg glimepiride. The maximum daily dose of pioglitazone is 30mg, and the maximum daily dose of glimepiride is 8mg. Failure to follow the appropriate dosage regimen may cause hypoglycemia. The initial dose of this drug should be based on the patient's current pioglitazone and/or sulfonylurea therapy. Patients sensitive to glucose-lowering agents should be closely monitored during dose adjustment. After starting this drug, closely monitor for adverse reactions associated with fluid retention. Changes in diabetes treatment may affect glycemic control, so use caution and ensure appropriate monitoring. After switching to this drug, closely monitor for hypoglycemia for 1-2 weeks. Allow sufficient time to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1c), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2-3 months. In clinical use of this drug, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1c is recommended. This drug should not be administered to patients with clinical evidence of active liver disease at the start of treatment or elevated serum transaminase levels (ALT greater than 2.5 times the upper limit of normal). Monitoring of liver enzymes is recommended in all patients before starting this drug and periodically thereafter. In patients with type 2 diabetes and systolic dysfunction, prescribe the lowest dose of this drug only if pioglitazone has been safely tolerated after titration from 15mg to 30mg. If further dose adjustments are required, closely monitor the patient for weight gain, edema, or signs and symptoms of worsening congestive heart failure (CHF).
This medication is used to treat type 2 diabetes and helps lower blood sugar levels. However, this medication should not be used in patients with severe heart function impairment, as it may present risks of worsening symptoms of heart failure. During treatment, if symptoms such as rapid weight gain or shortness of breath appear, consult a doctor immediately. Patients with a history of bladder cancer should carefully compare the risks of cancer recurrence with the benefits of blood glucose control when using this medication. Women who are pregnant or breastfeeding should avoid taking this medication, and pre-menopausal women are advised to use adequate contraception, as this medication may stimulate ovulation. This medication can affect liver function; therefore, regular liver function tests should be conducted before and during treatment, and if any signs of liver damage appear, notify medical personnel immediately. Due to the risk of hypoglycemia, particularly when co-administered with other glucose-lowering agents, it is important to be aware of hypoglycemic symptoms and to maintain regular eating and drinking habits. Elderly patients and those with impaired renal function have a higher risk of hypoglycemia, so careful dosage adjustments and monitoring are essential. Regular blood glucose and glycosylated hemoglobin tests should be conducted to check glucose control status while taking this medication, and if any unexpected side effects occur, consult a doctor immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture, ideally at room temperature between 1 and 30 degrees Celsius. This storage method helps maintain the medication's efficacy and safety.
White to grayish-white, convex round tablets
28 tablets (14 tablets/PTP packaging x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationPioglitazone Hydrochloride 33.06mg · Glimepiride 4mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationPioglitazone Hydrochloride 33.06mg · Glimepiride 2mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.